Immunome Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
IMNM Nasdaq 8731 https://immunome.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Immunome Inc

Analysts Estimate Immunome, Inc. (IMNM) to Report a Decline in Earnings: What to Look Out for - Apr 26th, 2024 2:00 pm
Immunome Appoints Sandra M. Swain to Board of Directors - Apr 25th, 2024 12:26 pm
Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting - Apr 5th, 2024 12:00 pm
New Strong Sell Stocks for April 4th - Apr 4th, 2024 9:56 am
Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets - Mar 28th, 2024 8:02 pm
Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala - Mar 26th, 2024 12:00 pm
Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome - Mar 26th, 2024 12:00 pm
Immunome, Inc. (NASDAQ:IMNM) surges 7.6%; individual investors who own 42% shares profited along with institutions - Mar 22nd, 2024 10:48 am
Immunome to Participate in the Leerink Partners Global Biopharma Conference - Mar 7th, 2024 1:00 pm
Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference - Mar 1st, 2024 1:00 pm
Immunome Recognizes Ayala Pharmaceuticals’ Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors - Feb 20th, 2024 1:15 pm
Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors - Feb 20th, 2024 1:00 pm
Immunome Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares - Feb 16th, 2024 9:05 pm
Immunome Announces Pricing of Public Offering of Common Stock - Feb 14th, 2024 3:38 am
Immunome Announces Proposed Public Offering of Common Stock - Feb 13th, 2024 9:05 pm
Insiders See US$1.25m Investment In Immunome Jump Last Week - Feb 10th, 2024 12:56 pm
Immunome (IMNM) to Acquire Desmoid Tumor Candidate, Stock Up - Feb 7th, 2024 1:34 pm
Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals - Feb 6th, 2024 1:00 pm
Immunome to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference - Feb 5th, 2024 1:00 pm
Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform - Jan 8th, 2024 12:00 pm